Profile cover photo
Profile photo
Corbus Pharma
12 followers -
Corbus Pharma (NASDAQ: CRBP) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs.
Corbus Pharma (NASDAQ: CRBP) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs.

12 followers
About
Corbus Pharma's posts

Post has attachment
Corbus Pharmaceuticals will be attending the 2016 ACR/ARHP Annual Meeting being held November 11th -16th in Washington, DC. Event information available here: http://bit.ly/2g7lE6M

Post has attachment
Corbus will be hosting an ice cream social open to the public on Wednesday September 7 from 2:30-3:30. Come support Team Corbus and learn how to get involved with the Cystic Fibrosis Foundation's Cycle for Life.
Photo

Post has attachment

Post has attachment
Visit our website to learn more about the rare, progressive autoimmune connective tissue disorder dermatomyositis believed to affect about one in 5,000 people. http://bit.ly/1JPAjG2

Thanks to all who came out last week to our Corbus Careers Happy Hour! We hope everyone had an enjoyable and informative evening!

Post has attachment

Post has attachment
Systemic sclerosis (also known as scleroderma) is a disfiguring, disabling and potentially fatal rare disease that causes scarring of the skin, lungs and other organs. Click here for facts, information and patient commentary on living with the disease. http://bit.ly/1UxtjmJ

Post has attachment
Corbus Pharmaceuticals Holdings, Inc. announced today that the U.S. Food and Drug Administration has granted approval for a 12-month open-label extension study of the ongoing Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis (“scleroderma”). The goal of the open label extension study is to provide all subjects with the option of receiving Resunab following the completion of the 84-day treatment period in the ongoing double-blind placebo-controlled study and to collect long term safety and efficacy data on Resunab. “We are delighted to be able to offer the patients in our systemic sclerosis trial the opportunity to continue in a 12-month, open-label extension study of Resunab, upon their competition of the blinded portion of the trial,” stated Barbara White, M.D., Chief Medical Officer of Corbus. “The additional 12 months of safety and efficacy data will be invaluable to the clinical advancement of this promising drug.” Read the full press release for more information: http://bit.ly/23AD4qO

Post has attachment

Post has attachment
Rare diseases are commonly misdiagnosed and pose a great unmet medical need due to lack of scientific knowledge. Without access to adequate medical care, complications can arise for patients. Rare Disease Day helped raise awareness for over 6,000 rare diseases worldwide. Click here to view ways you can still get involved:
Wait while more posts are being loaded